Sloothaak D A M, van der Linden R L A, van de Velde C J H, Bemelman W A, Lips D J, van der Linden J C, Doornewaard H, Tanis P J, Bosscha K, van der Zaag E S, Buskens C J
Department of Surgery, Gelre Hospital, Albert Schweitzerlaan 31, 7334 DZ, Apeldoorn, The Netherlands; Department of Surgery, Academic Medical Center, Postbus 22660, 1100DD, Amsterdam, The Netherlands.
Department of Surgery, Jeroen Bosch Hospital, PO Box 90153, 5200 ME, 's-Hertogenbosch, The Netherlands.
Eur J Surg Oncol. 2017 Aug;43(8):1456-1462. doi: 10.1016/j.ejso.2017.04.012. Epub 2017 May 5.
Occult nodal tumour cells should be categorised as micrometastasis (MMs) and isolated tumour cells (ITCs). A recent meta-analysis demonstrated that MMs, but not ITCs, are prognostic for disease recurrence in patients with stage I/II colon cancer.
AIMS & METHODS: The objective of this retrospective multicenter study was to correlate MMs and ITCs to characteristics of the primary tumour, and to determine their prognostic value in patients with stage I/II colon cancer.
One hundred ninety two patients were included in the study with a median follow up of 46 month (IQR 33-81 months). MMs were found in eight patients (4.2%), ITCs in 37 (19.3%) and occult tumour cells were absent in 147 patients (76.6%). Between these groups, tumour differentiation and venous or lymphatic invasion was equally distributed. Advanced stage (pT3/pT4) was found in 66.0% of patients without occult tumour cells (97/147), 72.9% of patients with ITCs (27/37), and 100% in patients with MMs (8/8), although this was a non-significant trend. Patients with MMs showed a significantly reduced 3 year-disease free survival compared to patients with ITCs or patients without occult tumour cells (75.0% versus 88.0% and 94.8%, respectively, p = 0.005). When adjusted for T-stage, MMs independently predicted recurrence of cancer (OR 7.6 95% CI 1.5-37.4, p = 0.012).
In this study, the incidence of MMs and ITCs in patients with stage I/II colon cancer was 4.2% and 19.3%, respectively. MMs were associated with an reduced 3 year disease free survival rate, but ITCs were not.
隐匿性淋巴结肿瘤细胞应分为微转移(MMs)和孤立肿瘤细胞(ITCs)。最近的一项荟萃分析表明,MMs而非ITCs对I/II期结肠癌患者的疾病复发具有预后意义。
这项回顾性多中心研究的目的是将MMs和ITCs与原发性肿瘤的特征相关联,并确定它们在I/II期结肠癌患者中的预后价值。
192例患者纳入本研究,中位随访时间为46个月(四分位间距33 - 81个月)。8例患者(4.2%)发现MMs,37例(19.3%)发现ITCs,147例患者(76.6%)未发现隐匿性肿瘤细胞。在这些组之间,肿瘤分化以及静脉或淋巴浸润分布均匀。无隐匿性肿瘤细胞的患者中66.0%(97/147)为晚期(pT3/pT4),ITCs患者中为72.9%(27/37),MMs患者中为100%(8/8),尽管这是一个无显著意义的趋势。与ITCs患者或无隐匿性肿瘤细胞的患者相比,MMs患者的3年无病生存率显著降低(分别为75.0%、88.0%和94.8%,p = 0.005)。校正T分期后,MMs可独立预测癌症复发(OR 7.6,95% CI 1.5 - 37.4,p = 0.012)。
在本研究中,I/II期结肠癌患者中MMs和ITCs的发生率分别为4.2%和19.3%。MMs与3年无病生存率降低相关,但ITCs并非如此。